Senesco Technologies Inc., of Bridgewater, N.J., opened two sites in the Republic of South Africa in its open-label, multiple-dose, dose-escalation phase Ib/IIa study of SNS01-T, which is evaluating the safety and tolerability in 15 patients with relapsed or refractory multiple myeloma or mantle cell or diffuse large B-cell lymphoma.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter